Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eiger Biopharma (EIGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study....

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia

PALO ALTO, Calif. , Aug. 13, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

PALO ALTO, Calif. , Aug. 10, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

PALO ALTO, Calif. , Aug. 7, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the Phase 2 LIFT Study...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health

PALO ALTO, Calif. , Aug. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the Notice of Allowance from...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals (EIGR) Enters Oversold Territory

Eiger BioPharmaceuticals, Inc. (EIGR) has been on a bit of a cold streak lately

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

EIGR : 9.60 (unch)
Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018(TM)

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation from the Phase 2 LOWR...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory, President and CEO, will present...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

PALO ALTO, Calif. , May 30, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

PALO ALTO, Calif. , May 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that...

EIGR : 9.60 (unch)
Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals

The Progeria Research Foundation (PRF) announced a collaboration and supply agreement with Eiger BioPharmaceuticals for the development and pursuit of U.S. Food and Drug Administration review and potential...

EIGR : 9.60 (unch)
Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months ended March...

EIGR : 9.60 (unch)
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018

PALO ALTO, Calif. , April 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV ( LO nafarnib ...

EIGR : 9.60 (unch)
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress(TM) 2018

Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The...

EIGR : 9.60 (unch)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC +0.54 , FTNT -0.51 , CAKE +0.54 , PLT +0.33 , AEO -0.09
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures ended the Monday session with most contracts 1 to 2 cents in the red. The USDA reported a private export sale of 213,372 MT to Mexico this morning, with the sale split between 2018/19 (142,248 MT) and 19/20 (71,124 MT). This morning&r...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar